Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thiazide-sensitive sodium-chloride cotransporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Voltage-gated T-type calcium channel blocker
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Migraine Disorders; Complex Regional Pain Syndromes; Neuralgia; Epilepsy, Absence; Irritable Bowel Syndrome; Seizures; Epilepsy
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Norepinephrine transporter releasing agent
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Obesity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thiazide-sensitive sodium-chloride cotransporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 1; Atherosclerosis; Cerebrovascular Disorders; Coronary Disease; Death, Sudden, Cardiac; Diabetes Mellitus; Diabetes Mellitus, Type 2; Essential Hypertension; Heart Diseases; Hypercholesterolemia; Myocardial Infarction; Myocardial Ischemia; Angina Pectoris; Cardiovascular Diseases; Glomerulonephritis; Heart Failure; Hypertension; Kidney Failure, Chronic; Nephrotic Syndrome; Toxemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Acetylcholinesterase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glaucoma
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bacterial Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thiazide-sensitive sodium-chloride cotransporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adrenergic receptor alpha-2 agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cough
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Norepinephrine transporter inhibitor
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Peripheral Nervous System Diseases; Pruritus; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sulfonylurea receptor 1, Kir6.2 blocker
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: ORAL; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Adenoma; Bronchiolitis; Dermatitis, Atopic; Dry Eye Syndromes; Glaucoma; Hyaline Membrane Disease; Macular Edema; Melanoma; Neck Pain; Respiratory Distress Syndrome, Newborn; Retinal Vein Occlusion; Sciatica; Tachypnea; Carpal Tunnel Syndrome; Cough; Eczema; Hypersensitivity; Lichen Planus, Oral; Orbital Pseudotumor; Pharyngitis; Pregnancy; Premature Birth; Psoriasis; Respiratory Distress Syndrome; Rhinitis, Allergic, Seasonal; Eye Diseases; Hemorrhoids; Lung Diseases, Obstructive; Nasal Obstruction
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Monoamine oxidase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder; Depressive Disorder, Major
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M1 antagonist
ROUTE OF ADMINISTRATION: INHALATION; INJECTION; INTRAMUSCULAR; INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; PEDIATRICS
THERAPEUTIC INDICATION: Depressive Disorder; Kidney Diseases; Sialorrhea; Hyperhidrosis; Asthma; Burns; Pulmonary Disease, Chronic Obstructive; Digestive System Diseases; Lung Diseases, Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: ORAL; RECTAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M1 antagonist
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Brain Injuries
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial dihydropteroate synthase inhibitor
ROUTE OF ADMINISTRATION: OPHTHALMIC; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY; OTHER
THERAPEUTIC INDICATION: Acne Vulgaris; Inflammation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Biliary Dyskinesia; Bursitis; Diabetes Mellitus; Digestive System Diseases; Intervertebral Disc Displacement; Lung Diseases, Interstitial; Paget Disease, Extramammary; Peripheral Nervous System Diseases; Anxiety; Cystitis, Interstitial; Dementia; Depressive Disorder, Major; Fibromyalgia; Headache; Migraine Disorders; Neuralgia; Pain; Schizophrenia; Sleep Initiation and Maintenance Disorders; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asthma; Severe Acute Respiratory Syndrome; Hyperhidrosis; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tubulin inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: MUSCULOSKELETAL; OTHER; RHEUMATOLOGY
THERAPEUTIC INDICATION: Liver Cirrhosis; Neoplasms; Urogenital Neoplasms; Acute Coronary Syndrome; Amyotrophic Lateral Sclerosis; Atherosclerosis; Behcet Syndrome; Cholangiocarcinoma; Coronavirus Infections; Diabetic Nephropathies; Heart Diseases; Hepatitis C, Chronic; Hypertension; Intracranial Hemorrhages; Myocardial Infarction; Osteoarthritis; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency, Chronic; Stomatitis, Aphthous; Vascular Diseases; Arrhythmias, Cardiac; Asthma; Atrial Fibrillation; Coronary Disease; Heart Failure; Liver Cirrhosis, Biliary; Lung Diseases; Non-ST Elevated Myocardial Infarction; Pericarditis; Postpericardiotomy Syndrome; ST Elevation Myocardial Infarction; Severe Acute Respiratory Syndrome; Vasculitis; Vitreoretinopathy, Proliferative; Familial Mediterranean Fever; Gout
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thiazide-sensitive sodium-chloride cotransporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Abdominal Pain; Alcoholism; Mitral Valve Insufficiency; Severe Acute Respiratory Syndrome; Hypersensitivity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cocaine-Related Disorders; Tobacco Use Disorder; Depressive Disorder, Major; Cushing Syndrome; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder, Major; Hypotension, Orthostatic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Anxiety; Dementia; Schizophrenia; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease; Hernia, Inguinal; Hypersensitivity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sulfonylurea receptor 1, Kir6.2 blocker
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Chronic Pain; Endotoxemia; Hepatitis C, Chronic; Lymphoma; Neoplasms; Diabetes Mellitus; Diabetes Mellitus, Type 2